Cargando…

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

INTRODUCTION: Immune complexes are of importance in systemic lupus erythematosus pathogenesis, and autoantibodies are believed to participate in immune complex formation. Quantification of autoantibody levels in circulating IC might be of prognostic value. METHODS: A C1q-binding-eluting technique wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohrabian, Azita, Parodis, Ioannis, Carlströmer-Berthén, Nellie, Frodlund, Martina, Jönsen, Andreas, Zickert, Agneta, Sjöwall, Christopher, Bengtsson, Anders A., Gunnarsson, Iva, Rönnelid, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884768/ https://www.ncbi.nlm.nih.gov/pubmed/31783909 http://dx.doi.org/10.1186/s13075-019-2056-y

Ejemplares similares

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus
por: Hedenstedt, Anna, et al.
Publicado: (2023)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus
por: Infantino, Maria, et al.
Publicado: (2021)

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis
por: Sjöwall, Christopher, et al.
Publicado: (2009)

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
por: Zickert, Agneta, et al.
Publicado: (2015)

Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons
por: Elbagir, Sahwa, et al.
Publicado: (2020)

Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis
por: Bolin, Karin, et al.
Publicado: (2013)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5
por: Sigurdsson, Snaevar, et al.
Publicado: (2008)

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study
por: Karlsson, Linnea, et al.
Publicado: (2023)

Anti-dsDNA Antibodies are one of the many autoantibodies in systemic lupus erythematosus
por: Fu, Shu Man, et al.
Publicado: (2015)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus
por: Biesen, Robert, et al.
Publicado: (2011)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up
por: Gerhardsson, Jakob, et al.
Publicado: (2015)

Sex differences in clinical presentation of systemic lupus erythematosus
por: Ramírez Sepúlveda, Jorge I., et al.
Publicado: (2019)

Autoantibodies to dsDNA in the diagnosis, classification and follow-up of patients with systemic lupus erythematosus
por: Damoiseaux, Jan, et al.
Publicado: (2023)

ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
por: Leonard, Dag, et al.
Publicado: (2018)

The Effects of Flexibility on dsDNA–dsDNA Interactions
por: Chen, Chuanying, et al.
Publicado: (2022)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus
por: Jönsen, Andreas, et al.
Publicado: (2011)

Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2019)

Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active Disease
por: Villalta, Danilo, et al.
Publicado: (2013)

Differential DNA methylation associated with anti-dsDNA autoantibody production in systemic lupus erythematosus
por: Chung, SA, et al.
Publicado: (2012)

Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti–dsDNA Autoantibody Production
por: Chung, Sharon A., et al.
Publicado: (2011)

Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus
por: Torell, Agnes, et al.
Publicado: (2023)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Contributions of de novo variants to systemic lupus erythematosus
por: Almlöf, Jonas Carlsson, et al.
Publicado: (2020)

Comment on: Sudanese and Swedish patients with systemic lupus erythematosus, immunological and clinical comparisons: reply
por: Elbagir, Sahwa, et al.
Publicado: (2020)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2020)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017)

NET Formation in Systemic Lupus Erythematosus: Changes during the COVID-19 Pandemic
por: Knopf, Jasmin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gm5smse73elbaph015unbm6lhm